Based on published as well as our current results we hypothesize that the combination of hypericin-PDT and 17-DMAG could have a great impact in clinical applications at least in the treatment of chest wall recurrence of HER2 positive breast carcinoma. Here, ERBB2 is linked to breast carcinoma.